fenofibrate has been researched along with Albuminuria in 11 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 9.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 9.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "We investigated effects of renal function and albuminuria on cardiovascular outcomes in 9,795 low-risk patients with diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 7.77 | Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Ansquer, JC; Colman, P; Davis, TM; Dixon, P; Drury, PL; Ehnholm, C; Fassett, R; Flack, J; Keech, A; Pardy, C; Ting, R; Whiting, M; Zannino, D, 2011) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 5.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| "In people with type 2 diabetes at high risk for cardiovascular disease, intensive glycemic control may result in a long-term reduction in macroalbuminuria; however, intensive BP control and fenofibrates may increase the risk for adverse kidney events." | 5.27 | Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. ( Buse, JB; Craven, TE; Ismail-Beigi, F; Katz, L; Mottl, AK; Mychaleckyj, JC; Papademetriou, V; Pedley, CF; Sigal, RJ; Simmons, DL, 2018) |
| "Although fenofibrate was associated with less progression of albuminuria in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, it is unknown if it has any effect on renal function." | 5.14 | Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. ( Forsblom, C; Groop, PH; Hiukka, A; Leinonen, ES; Sundvall, J; Taskinen, MR, 2010) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 5.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "Elevated circulating FFA level may cause increased microalbuminuria in obese rats due to impairment of EDV; increased microalbuminuria can be improved by fenofibrate intervention." | 3.79 | High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats. ( Han, L; Sun, X; Yu, Y, 2013) |
| "We investigated effects of renal function and albuminuria on cardiovascular outcomes in 9,795 low-risk patients with diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study." | 3.77 | Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. ( Ansquer, JC; Colman, P; Davis, TM; Dixon, P; Drury, PL; Ehnholm, C; Fassett, R; Flack, J; Keech, A; Pardy, C; Ting, R; Whiting, M; Zannino, D, 2011) |
| "In adults with type 2 diabetes and known or suspected atherosclerosis, arterial smooth muscle-dependent dilatation was shown to be significantly impaired in cigarette smokers and those with elevated urinary albumin levels." | 2.79 | Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy. ( Celermajer, DS; Harmer, JA; Keech, AC; Marwick, TH; Meredith, IT; Skilton, MR; Veillard, AS; Watts, GF, 2014) |
| "Fenofibrate was administered 4 wk after the initiation of the HFD when renal injury was initiated." | 1.46 | Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy. ( Ha, H; Hwang, I; Kang, H; Kim, H; Kim, K; Lee, G; Lee, JH; Sohn, M; Uddin, MJ, 2017) |
| "Fenofibrate treatment dramatically reduced fasting blood glucose (P<0." | 1.33 | PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. ( Breyer, M; Cha, DR; Chen, L; Davis, L; Fan, X; Guan, Y; Hwang, MT; Park, CW; Striker, G; Su, D; Wu, J; Zhang, X; Zhang, Y; Zheng, F, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, X | 2 |
| Liu, J | 1 |
| Wang, G | 1 |
| Mottl, AK | 1 |
| Buse, JB | 1 |
| Ismail-Beigi, F | 1 |
| Sigal, RJ | 1 |
| Pedley, CF | 1 |
| Papademetriou, V | 1 |
| Simmons, DL | 1 |
| Katz, L | 1 |
| Mychaleckyj, JC | 1 |
| Craven, TE | 1 |
| Yu, Y | 1 |
| Han, L | 1 |
| Harmer, JA | 1 |
| Keech, AC | 1 |
| Veillard, AS | 1 |
| Skilton, MR | 1 |
| Marwick, TH | 1 |
| Watts, GF | 1 |
| Meredith, IT | 1 |
| Celermajer, DS | 1 |
| Sohn, M | 1 |
| Kim, K | 1 |
| Uddin, MJ | 1 |
| Lee, G | 1 |
| Hwang, I | 1 |
| Kang, H | 1 |
| Kim, H | 1 |
| Lee, JH | 1 |
| Ha, H | 1 |
| Steiner, G | 2 |
| Forsblom, C | 1 |
| Hiukka, A | 1 |
| Leinonen, ES | 1 |
| Sundvall, J | 1 |
| Groop, PH | 1 |
| Taskinen, MR | 2 |
| Drury, PL | 1 |
| Ting, R | 1 |
| Zannino, D | 1 |
| Ehnholm, C | 1 |
| Flack, J | 1 |
| Whiting, M | 1 |
| Fassett, R | 1 |
| Ansquer, JC | 2 |
| Dixon, P | 1 |
| Davis, TM | 1 |
| Pardy, C | 1 |
| Colman, P | 1 |
| Keech, A | 1 |
| Hermans, MP | 1 |
| Foucher, C | 1 |
| Rattier, S | 1 |
| Park, CW | 1 |
| Zhang, Y | 1 |
| Zhang, X | 1 |
| Wu, J | 1 |
| Chen, L | 1 |
| Cha, DR | 1 |
| Su, D | 1 |
| Hwang, MT | 1 |
| Fan, X | 1 |
| Davis, L | 1 |
| Striker, G | 1 |
| Zheng, F | 1 |
| Breyer, M | 1 |
| Guan, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy[NCT02314533] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy[NCT03869931] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fenofibrate and Albuminuria
| Article | Year |
|---|---|
How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.
Topics: Albuminuria; Amputation, Surgical; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2009 |
Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.
Topics: Albuminuria; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Evidence-Based Medicine; Fenofibrate; | 2011 |
5 trials available for fenofibrate and Albuminuria
| Article | Year |
|---|---|
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Gl | 2020 |
Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Ty | 2018 |
Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy.
Topics: Aged; Albuminuria; Brachial Artery; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, V | 2014 |
Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Female; Fen | 2010 |
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
4 other studies available for fenofibrate and Albuminuria
| Article | Year |
|---|---|
High FFA levels related to microalbuminuria and uncoupling of VEGF-NO axis in obese rats.
Topics: Albuminuria; Analysis of Variance; Animals; Biopsy, Needle; Blotting, Western; Diet, High-Fat; Disea | 2013 |
Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Autophagy; Diabetic Nephropathies; Diet, High-F | 2017 |
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Topics: Aged; Albuminuria; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glomerul | 2011 |
PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.
Topics: Albuminuria; Animals; Blood Glucose; Body Weight; Cells, Cultured; Collagen Type I; Diabetes Mellitu | 2006 |